Los investigadores patentan un tratamiento farmacológico para aumentar la producción de proteínas en el cerebro
noviembre 30, 2016
![](https://www.theaftd.org/wp-content/plugins/bb-plugin/img/pixel.png)
Como reportado en Twin Cities Business on November 23rd, a team of researchers has patented a drug treatment that stimulates the production of progranulin (PGRN), a protein necessary in maintaining the health of the brain’s frontal and temporal lobes. Deficiencies of PGRN have been linked to both FTD and ALS. The researchers — led by the Mayo Clinic’s Rosa Rademakers, who received the Potamkin Prize earlier this year — also patented a benign virus designed to deliver the drug to the brain.
Por categoria
Nuestros boletines
Mantente informado
![icono-de-color-portátil color-icon-laptop](/wp-content/uploads/2021/09/color-icon-laptop.png)
Regístrese ahora y manténgase al tanto de las últimas novedades con nuestro boletín informativo, alertas de eventos y más...